SECOND GENOME, INC.
Platform service analyzing gut microbiome samples to identify metabolites and CNS disease biomarkers for autism and substance use disorder research
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2009
- Latest Form D
- $5M, Aug 2011
- Total capital
- $7.9M
- Federal grants
- $2.1M
- 3 awards · 2017–2020
- Rank in peer group#1 of 37
- Private capital raised
- $5M
- 1 Form D · last Aug 2011
- 183 months since last filing
- Federal contracts
- $834K
- 19 awards · Interior, Defense, Environmental Prot
- Rank in Biotech#200 of 4373
- Granted patents
- 10
- 30 pending · first 2018
- Rank in peer group#2 of 37
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders$967K
- Federal grantHealth and Human S · Phase II · Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders$977K
- Federal contractEnvironmental Prot · Purchase 95 Phylochips And 100 Rxns (4 Tubes) Of Spike Mix For The Region 7 Laboratory$25K
- Federal contractEnvironmental Prot · Purchase 98 G3 Phylochips And 4 Tubes Of Spike Mix$25K
- Federal contractHealth and Human S · Igf::ot::igf Microbiome Optimized Dna Isolation Services$81K
- Federal contractAgriculture · Igf::ct::igf Custom Wetland Analysis Services For Dr. Mark Ibekwe.$4K
- Federal grantHealth and Human S · Phase II · Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders$149K
- Private capital raisedForm D · SEC · 1st filing$5M
Show 15 earlier federal awards
- Federal contractHealth and Human S · Igf::ot::igf - Second Genome, INC.:1202409 [16-012878]JKRAKOFF$12K
- Federal contractHealth and Human S · Igf::cl::igf$250
- Federal contractAgriculture · Microbiome Signature Discovery Service: V4 16S Sequencing And Bioinformatics For Academic Clients (81 Samples), Contaminant Fate&transport Unit, Riverside, Ca Igf::ct::igf$15K
- Federal contractHealth and Human S · Igf::cl::igf Service$5K
- Federal contractHealth and Human S · Igf::cl::igf Service$5K
- Federal contractHealth and Human S · Igf::ot::igf Rrna Sequencing$16K
- Federal contractAgriculture · Microbiome Discovery Photochip Assay$21K
- Federal contractHealth and Human S · Igf::ct::igf Service$43K
- Federal contractCommerce · Sabelfish Nutrition Experiment$28K
- Federal contractAgriculture · Microbial Profiling Service Quote #00000153$15K
- Federal contractNASA · Microbial Profiling Service Using Phylochip Technology For Planetary Protection Spacecraft Bioburden Analysis.$10K
- Federal contractHealth and Human S · Identify The Bacterial Composition In The Gut From Pair-fedðanol-fed Mice$10K
- Federal contractEnvironmental Prot · Phylogenetic Microarray Services$498K
- Federal contractDefense · Microbial Profiling$11K
- Federal contractInterior · Grnd Water Sample Analysis-lisle$12K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
8months
from SECOND GENOME, INC.’s first federal award to its first private round.
- First federal award · Dec 2010
- Interior · $12K
- First Form D · Aug 2011
- $5M · 1st Form D
- Awards before first raise
- 3 awards
An association in public records, not a cause or a prediction.
Standing among 37 peers
Line = medianBiotech · Platform
- Federal grants#1 · top 3%
- Granted patents#2 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Corey GoodmanDirectorNamed in SEC Form D filings
- Jason LettmannDirectorNamed in SEC Form D filings
- Matthew WinklerDirectorNamed in SEC Form D filings
- Michael CarusiDirectorNamed in SEC Form D filings
- Peter DiLauraExecutive Officer, DirectorNamed in SEC Form D filings
- Peter GardnerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 10 granted of 40- GrantedProteins For The Treatment Of Epithelial Barrier Function DisordersUSPTOUS 11,666,627
- PendingMethods And Compositions For Treating Type 2 DiabetesUSPTOApplication 17758748
- PendingMethods And Compositions For Treating Atopic DermatitisUSPTOApplication 17758773
Show all 40 patent records
- Proteins For The Treatment Of Epithelial Barrier Function DisordersJun 6, 2023 · US 11,666,627Granted
- Methods And Compositions For Treating Type 2 DiabetesFeb 2, 2023 · Application 17758748Pending
- Methods And Compositions For Treating Atopic DermatitisFeb 2, 2023 · Application 17758773Pending
- Methods And Compositions For Treating Ulcerative ColitisFeb 2, 2023 · Application 17758713Pending
- Methods And Compositions For Treating Colorectal CancerFeb 2, 2023 · Application 17758777Pending
- Proteins for the Treatment of Epithelial Barrier Function DisordersNov 22, 2022 · US 11,505,583Granted
- Methods For Validation Of Microbiome Sequence Processing And Differential Abundance Analyses Via Multiple Bespoke Spike-in MixturesOct 18, 2022 · US 11,473,133Granted
- Streptococcus Australis As A BiotherapeuticJul 19, 2022 · US 11,389,487Granted
- Proteins For The Treatment Of Epithelial Barrier Function DisordersJun 16, 2022 · Application 16614226Pending
- Gemella Sanguinis As A BiotherapeuticMay 31, 2022 · US 11,344,584Granted
- Proteins For The Treatment Of Epithelial Barrier Function DisordersApr 7, 2022 · Application 17526970Pending
- Proteins For The Treatment Of Epithelial Barrier Function DisordersMar 15, 2022 · US 11,273,198Granted
- Proteins For The Treatment Of Epithelial Barrier Function DisordersDec 28, 2021 · US 11,207,376Granted
- Proteins For The Treatment Of Epithelial Barrier Function DisordersNov 16, 2021 · US 11,174,293Granted
- Microbial Ecology Shift AssayMay 9, 2019 · Application 16181590Pending
- Proteins For The Treatment Of Epithelial Barrier Function DisordersApr 9, 2019 · US 10,251,933Granted
- Microbial Ecology Shift AssayDec 11, 2018 · US 10,150,982Granted
- Microbiome Modulation IndexNov 26, 2015 · Application 14758934Pending
- Methods And Compositions For Treating Colorectal CancerApplication 62962827Pending
- Microbially Derived Peptides And Proteins For ImmunotherapyApplication PCTUS2020012431Pending
- Methods and Compositions for Treating Inflammatory DiseasesApplication 62928232Pending
- Lactococcus Lactis Expression System For Delivering Proteins Efficacious For The Treatment Of Epithelial Barrier Function DisordersApplication PCTUS2019055476Pending
- Compositions, Systems, Apparatuses, And Methods For Validation Of Microbiome Sequence Processing And Differential Abundance Analyses Via Multiple Bespoke Spike-in MixturesApplication PCTUS2019052802Pending
- Methods for Treating Inflammatory Bowel DiseaseApplication 62834336Pending
- Proteins For The Treatment Of Epithelial Barrier Function DisordersApplication PCTUS2019026412Pending
- Microbially Derived Peptides And Proteins For ImmunotherapyApplication 62788950Pending
- Use Of A P2X7 Receptor Antagonist To Treat An Inflammatory Disease Or DisorderApplication PCTUS2018061037Pending
- Lactococcus Lactis Expression System For Delivering Proteins Efficacious For The Treatment Of Epithelial Barrier Function DisordersApplication 62743372Pending
- Compositions, Systems, Apparatuses, And Methods For Validation Of Microbiome Sequence Processing And Differential Abundance Analyses Via Multiple Bespoke Spike-in MixturesApplication 62735374Pending
- Streptococcus Australis As A BiotherapeuticsApplication PCTUS2018045330Pending
- Gemella Sanguinis As A BiotherapeuticsApplication PCTUS2018045329Pending
- Roseburia Hominis, Eubacterium Eligens, And Combinations Thereof As BiotherapeuticsApplication PCTUS2018045239Pending
- Proteins For The Treatment Of Epithelial Barrier Function DisordersApplication PCTUS2018035682Pending
- Proteins For The Treatment Of Epithelial Barrier Function DisordersApplication PCTUS2018033347Pending
- Proteins For The Treatment Of Epithelial Barrier Function DisordersApplication PCTUS2018031046Pending
- Use Of A P2X7 Receptor Antagonist To Treat An Inflammatory Disease Or DisorderApplication 62655660Pending
- Proteins For The Treatment Of Epithelial Barrier Function DisordersApplication PCTUS2018026447Pending
- Proteins for the Treatment of Epithelial Barrier Function DisordersApplication 62654083Pending
- Stable Proteins For The Treatment Of Gastrointestinal Inflammatory Conditions And Epithelial Barrier Function DisordersApplication 62611334Pending
- Proteins For The Treatment Of Gastrointestinal Inflammatory Conditions And Epithelial Barrier Function DisordersApplication 62607706Pending
Related companies, and why
- Nanoscience Solutions, LLCSimilar federal contract value in Biotech · $849K in contracts
- INTRA-CELLULAR THERAPIES, INC.Similar federal contract value in Biotech · $849K in contracts
- ENERGESIS PHARMACEUTICALS INCSimilar federal contract value in Biotech · $849K in contracts
- Planet Biotechnology IncorporatedSimilar federal contract value in Biotech · $828K in contracts
- SUJANA BIOTECH, LLCSimilar federal contract value in Biotech · $783K in contracts
- JUMPCODE GENOMICSSimilar federal contract value in Biotech · $765K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .